S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
NASDAQ:MTP

Midatech Pharma - MTP Stock Forecast, Price & News

$1.65
-0.03 (-1.78%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.63
$1.65
50-Day Range
$1.51
$2.60
52-Week Range
$1.29
$7.45
Volume
3,196 shs
Average Volume
8,479 shs
Market Capitalization
$6.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MTP stock logo

About Midatech Pharma (NASDAQ:MTP) Stock

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Receive MTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Midatech Pharma and its competitors with MarketBeat's FREE daily newsletter.

MTP Stock News Headlines

MTP Midatech Pharma plc
Midatech Pharma PLC Announces ADR Ratio Change
Midatech Pharma PLC News
Midtech Booms on Discovery
Stock Alert: Midatech Pharma Jumps 40%
Midatech Pharma PLC Announces Business Update
Midatech Pharma PLC Announces Launch of new website
See More Headlines
Receive MTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Midatech Pharma and its competitors with MarketBeat's FREE daily newsletter.

MTP Company Calendar

Today
12/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MTP
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$800,000.00
Book Value
$5.67 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.52 million
Optionable
Not Optionable
Beta
2.33

Key Executives

  • Mr. Stephen A. Stamp (Age 60)
    CEO, CFO, Company Sec. & Director
    Comp: $282.28k
  • Dr. Dmitry Zamoryakhin M.D. (Age 42)
    Chief Scientific Officer
    Comp: $279.38k
  • Dr. Daniel Palmer MBA
    Ph.D., VP of Technology
  • Dr. Tim Sparey Ph.D.
    Chief Bus. Officer
  • Mr. Justin Barry BSc (Hons.)
    MBIOL, CBIOL, QP, Head of Manufacturing
  • Mr. David Benharris (Age 57)
    Pres of Midatech Pharma US Inc
  • Ms. Fiona Sharp
    Group Financial Controller













MTP Stock - Frequently Asked Questions

How have MTP shares performed in 2022?

Midatech Pharma's stock was trading at $5.25 at the beginning of the year. Since then, MTP stock has decreased by 68.5% and is now trading at $1.6546.
View the best growth stocks for 2022 here
.

When did Midatech Pharma's stock split?

Midatech Pharma's stock reverse split on Monday, September 26th 2022. The 1-5 reverse split was announced on Monday, September 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Midatech Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Midatech Pharma investors own include CRISPR Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), Plug Power (PLUG), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

What is Midatech Pharma's stock symbol?

Midatech Pharma trades on the NASDAQ under the ticker symbol "MTP."

Who are Midatech Pharma's major shareholders?

Midatech Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.95%).

How do I buy shares of Midatech Pharma?

Shares of MTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Midatech Pharma's stock price today?

One share of MTP stock can currently be purchased for approximately $1.65.

How much money does Midatech Pharma make?

Midatech Pharma (NASDAQ:MTP) has a market capitalization of $6.52 million and generates $800,000.00 in revenue each year.

How can I contact Midatech Pharma?

Midatech Pharma's mailing address is ODDFELLOWS HOUSE 19 NEWPORT ROAD, CARDIFF X0, CF24 0AA. The official website for the company is www.midatechpharma.com. The company can be reached via phone at 441235888300 or via email at ir@midatechpharma.com.

This page (NASDAQ:MTP) was last updated on 12/3/2022 by MarketBeat.com Staff